E-Therapeutics PLC
LSE:ETX
Intrinsic Value
e-Therapeutics Plc is a drug discovery and development company, which engages in the provision of evaluation services to investors and pharmaceutical companies. [ Read More ]
The intrinsic value of one
ETX
stock under the Base Case scenario is
1.246
GBX.
Compared to the current market price of 9.175 GBX,
E-Therapeutics PLC
is
Overvalued by 86%.
ETX's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
ETX or that its price is influenced by factors unrelated to fundamentals.
E-Therapeutics PLC's market capitalization is 53.4m GBX.
ETX stock price is 9.175 GBX.
ETX stock (1.246 GBX) is 86% less than its price (9.175 GBX).
ETX stock (0.938 GBX) is 90% less than its price (9.175 GBX). Open Relative Valuation
ETX's Revenue has dropped by 0% over the past 12 months.
ETX's ROE (Return on Equity) has significantly increased in the last 3 years from -40% to -27%, and is approaching profitability.
ETX's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -438% to -473%, and is approaching profitability.
ETX has negative Operating Income for the last twelve months.
ETX has negative Net Income for the last twelve months.
ETX's ROE (Return on Equity) for the past 12 months is negative and is equal to -27%.
ETX's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -473%.
ETX has positive Gross Profit for the last twelve months.
ETX has negative Free Cash Flow for the last twelve months.
ETX has negative three-year average ROE (Return on Equity): -33%. The company is not efficient at transforming stockholders' equity into net income.
ETX has negative three-year average ROIC (Return on Invested Capital): -422%. The company is not efficient at using invested capital to generate operating income.
ETX's short-term assets (34m GBP) exceed its short-term liabilties (2m GBP).
ETX's long-term assets (35m GBP) exceed its long-term liabilties (2m GBP).
ETX's D/E (Debt to Equity) is very low and is equal to 0.
ETX's Altman Z-Score is very high and is equal to 31.06.
ETX doesn't generate enough operating income (-10m GBP) to safely cover interest payments on its debt (23k GBP).
Valuation Backtest
E-Therapeutics PLC
Run backtest to discover the historical profit from buying and selling
ETX
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
E-Therapeutics PLC
Balance Sheet Decomposition
E-Therapeutics PLC
| Current Assets | 34m |
| Cash & Short-Term Investments | 31.7m |
| Receivables | 1.8m |
| Other Current Assets | 553k |
| Non-Current Assets | 639k |
| PP&E | 400k |
| Intangibles | 239k |
| Current Liabilities | 1.6m |
| Accounts Payable | 1.3m |
| Other Current Liabilities | 295k |
Earnings Waterfall
E-Therapeutics PLC
|
Revenue
|
475k
GBP
|
|
Cost of Revenue
|
0
GBP
|
|
Gross Profit
|
475k
GBP
|
|
Operating Expenses
|
-10.7m
GBP
|
|
Operating Income
|
-10.2m
GBP
|
|
Other Expenses
|
2m
GBP
|
|
Net Income
|
-8.3m
GBP
|
Free Cash Flow Analysis
E-Therapeutics PLC
ETX Profitability Score
Profitability Due Diligence
E-Therapeutics PLC's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
E-Therapeutics PLC's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
ETX Solvency Score
Solvency Due Diligence
E-Therapeutics PLC's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Score
E-Therapeutics PLC's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ETX Price Targets Summary
E-Therapeutics PLC
According to Wall Street analysts, the average 1-year price target for
ETX
is 10 GBX
.
Shareholder Return
ETX Price
E-Therapeutics PLC
| Average Annual Return | 135.97% |
| Standard Deviation of Annual Returns | 230.14% |
| Max Drawdown | -83% |
| Market Capitalization | 53.4m GBX |
| Shares Outstanding | 582 694 162 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
E-Therapeutics PLC
Country
Industry
Market Cap
Dividend Yield
Description
e-Therapeutics Plc is a drug discovery and development company, which engages in the provision of evaluation services to investors and pharmaceutical companies. The company is headquartered in Witney, Oxfordshire and currently employs 18 full-time employees. The company went IPO on 2007-11-28. The firm's platform is a combination of databases and a suite of computational tools that employ network analysis, data mining, machine learning, artificial intelligence (Al) and optimization. Its in silico platform serves as a laboratory, which enables it to computationally test potential therapeutic interventions. Its network-driven drug discovery (NDD) technology performs computational phenotypic screens to identify efficacious drugs. Its genome-associated interactions networks (GAINs) technology interprets genomic data in the context of the biological networks, in which the genes function. Its ribonucleic acid (RNA) Interference, (RNAi) platform is in development to complement its computational toolset. The firm identifies new therapeutic approaches to modulate a specific mechanism involved in Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic indications through Galapagos NV (Galapagos).
Contact
IPO
Employees
Officers
The intrinsic value of one
ETX
stock under the Base Case scenario is
1.246
GBX.
Compared to the current market price of 9.175 GBX,
E-Therapeutics PLC
is
Overvalued by 86%.
You don't have any saved screeners yet
